Tysabri

Drug Overview
Product Profiles
Tysabri: Crohn's disease
Tysabri: Multiple sclerosis (MS)

Figure 5: Patient-based forecast methodology for COPD
Figure 10: Anoro for COPD – SWOT analysis
Figure 38: Stiolto Respimat for COPD – SWOT analysis
Figure 7: The authors drug assessment summary of Advair for COPD
Figure 12: Arcapta for COPD – SWOT analysis
Figure 9: The authors drug assessment summary of Advair for COPD

Table 2: Tysabri pivotal trial data in Crohn’s disease
Table 3: Tysabri sales for Crohn’s disease in the US ($m), 2016–25
Table 4: Tysabri drug profile
Table 5: Tysabri pivotal trial data in multiple sclerosis
Table 6: Tysabri sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25